Advertisement

Archives of Virology

, Volume 154, Issue 6, pp 1005–1007 | Cite as

Efficacy of phthalocyanine tetrasulfonate against mouse-adapted human prion strains

  • Hanin Abdel-Haq
  • Mei Lu
  • Franco Cardone
  • Quan Guo Liu
  • Maria Puopolo
  • Maurizio Pocchiari
Brief Report

Abstract

In vitro and in vivo studies have shown that phthalocyanine tetrasulfonate (PcTS), a cyclic tetrapyrrole compound, is an efficient antiscrapie drug. To investigate the spectrum of PcTS against prion diseases, we tested the effect of PcTS on two mouse-adapted human strains. We also tested PcTS in rodents infected with two scrapie strains (139A and 263K). PcTS treatment significantly prolonged mean survival times of all infected animals. These results show that PcTS is effective on different prion strains, confirming its potential use for prion therapy.

Keywords

Scrapie 263K Strain Transmissible Spongiform Encephalopathy Pentosan Polysulfate Prion Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The skillful technical assistance of Nicola Bellizzi, Maurizio Bonanno, Ivano Itro, and Elfino Laconi is gratefully acknowledged. We thank Dr. Alessandra Garozzo and Mr. Marco Del Re for editorial assistance. This work was partially supported by the Istituto Superiore di Sanità, and by the “Progetto multidisciplinare sulla terapia delle malattie da virus”.

References

  1. 1.
    Trevitt CR, Collinge JA (2006) Systematic review of prion therapeutics in experimental models. Brain 129:2241–2265PubMedCrossRefGoogle Scholar
  2. 2.
    Todd NV, Morrow J, Doh-ura K, Dealler S, O’Hare S, Farling P, Duddy M, Rainov NG (2005) Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. J Infect 50:394–396PubMedCrossRefGoogle Scholar
  3. 3.
    Bone I, Belton L, Walker AS, Darbyshire J (2008) Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 15:458–464PubMedCrossRefGoogle Scholar
  4. 4.
    Forloni G, Salmona M, Marcon G, Tagliavini F (2009) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9:23–30PubMedGoogle Scholar
  5. 5.
    Stewart LA, Rydzewska LH, Keogh GF, Knight RS (2008) Systematic review of therapeutic interventions in human prion disease. Neurology 70:1272–1281PubMedCrossRefGoogle Scholar
  6. 6.
    Caughey WS, Raymond LD, Horiuchi M, Caughey B (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 95:12117–12122PubMedCrossRefGoogle Scholar
  7. 7.
    Caughey WS, Priola SA, Kocisko DA, Raymond LD, Ward A, Caughey B (2007) Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob Agents Chemother 51:3887–3894PubMedCrossRefGoogle Scholar
  8. 8.
    Priola SA, Raines A, Caughey W (2003) Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J Infect Dis 188:699–705PubMedCrossRefGoogle Scholar
  9. 9.
    Priola SA, Raines A, Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds. Science 287:1503–1506PubMedCrossRefGoogle Scholar
  10. 10.
    Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BØ, Angellpetersen E, Warloe T, Frandsen N, Høgset A (2005) Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 218:133–147PubMedCrossRefGoogle Scholar
  11. 11.
    Wainwright M (2008) Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem 8:280–291PubMedCrossRefGoogle Scholar
  12. 12.
    Kocisko DA, Caughey B, Morrey JD, Race RE (2006) Enhanced antiscrapie effect using combination drug treatment. Antimicrob Agents and Chemother 50:3447–3449CrossRefGoogle Scholar
  13. 13.
    Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ (1997) Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389:498–501PubMedCrossRefGoogle Scholar
  14. 14.
    Tateishi J, Ohta M, Koga M, Sato Y, Kuroiwa Y (1979) Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol 5:581–584PubMedCrossRefGoogle Scholar
  15. 15.
    Kimberlin RH, Walker CA, Fraser H (1989) The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J Gen Virol 70:2017–2025PubMedCrossRefGoogle Scholar
  16. 16.
    Berardi VA, Cardone F, Valanzano A, Lu M, Pocchiari M (2006) Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation. Transfusion 46:652–658PubMedCrossRefGoogle Scholar
  17. 17.
    Xi YG, Cardone F, Pocchiari M (1994) Detection of proteinase-resistant protein (PrP) in small brain tissue samples from Creutzfeldt–Jakob disease patients. J Neurol Sci 124:171–173PubMedCrossRefGoogle Scholar
  18. 18.
    Demaimay R, Race R, Chesebro B (1999) Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J Virol 73:3511–3513PubMedGoogle Scholar
  19. 19.
    Pocchiari M, Ladogana A, Graziano S, Puopolo M (2008) Creutzfeldt–Jakob disease: hopes for therapy. Eur J Neurol 15:435–436PubMedCrossRefGoogle Scholar
  20. 20.
    Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC (2006) Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5:393–398PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Hanin Abdel-Haq
    • 1
  • Mei Lu
    • 1
  • Franco Cardone
    • 1
  • Quan Guo Liu
    • 1
  • Maria Puopolo
    • 1
  • Maurizio Pocchiari
    • 1
  1. 1.Department of Cell Biology and NeurosciencesIstituto Superiore di SanitàRomeItaly

Personalised recommendations